Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease

[Candeias]

Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease

"Two months of pterostilbene diet but not resveratrol significantly improved radial arm water maze function in SAMP8 compared with control-fed animals. Neither resveratrol nor pterostilbene increased sirtuin 1 (SIRT1) expression or downstream markers of sirtuin 1 activation. Importantly, markers of cellular stress, inflammation, and AD pathology were positively modulated by pterostilbene but not resveratrol and were associated with upregulation of peroxisome proliferator-activated receptor (PPAR) alpha expression. (...)"

It hasn't been talked about much on the forum yet but it seems to have multifaceted protective properties even at doses that don't increase SIRT1. Its high absorption rate also caught my attention.

Thoughts?

 

[cdg]

See also: WordWeb Online Lookup

 

[GTW]

Noting the publication date, 2012.
Volumes of research in this area, ensuing ten years
Fisitin seems to be a new Wunderkind in the same family.

Fisetin as a Senotherapeutic Agent: Biopharmaceutical Properties and Crosstalk between Cell Senescence and Neuroprotection

Like other organs, brain functions diminish with age. Furthermore, for a variety of neurological disorders—including Alzheimer’s disease—age is one of the higher-risk factors. Since in many Western countries the average age is ...

www.ncbi.nlm.nih.gov

 

[Candeias]

Pterostilbene raises low density lipoprotein cholesterol in people


Probably only safe in small doses, given this study as well

 

[Candeias]

A Review of Pterostilbene Antioxidant Activity and Disease Modification

Pterostilbene raises low density lipoprotein cholesterol in people


Probably only safe in small doses, given this study as well

However

Pterostilbene protects vascular endothelial cells against oxidized low-density lipoprotein-induced apoptosis in vitro and in vivo

"PT inhibited the expression of lectin-like oxLDL receptor-1 (LOX-1) expression in vitro and in vivo. Cotreatment with PT and siRNA of LOX-1 synergistically reduced oxLDL-induced apoptosis in HUVECs. Overexpression of LOX-1 attenuated the protection by PT and suppressed the effects of PT on oxLDL-induced oxidative stress. PT may protect HUVECs against oxLDL-induced apoptosis by downregulating LOX-1-mediated activation through a pathway involving oxidative stress, p53, mitochondria, cytochrome c and caspase protease. PT might be a potential natural anti-apoptotic agent for the treatment of atherosclerosis."